❯ AI simulation company Simile raises $200M at $2B post-money, just five months after last round

LEAPAccording to a July 30 announcement, AI simulation company Simile closed a Series B of more than $200M, with a $2B post-money valuation, led by Greenoaks, with Index Ventures, Bain Capital Ventures, CVS Health Ventures and others participating. The company builds synthetic users — using AI to simulate how real populations behave and respond, replacing traditional focus groups and user research. Headquartered in Palo Alto, California, it now has more than 50 employees.

TIMELINEThe timeline is the most striking thing about this deal. In February 2026, Simile had just come out of stealth with a $100M Series A led by Index Ventures; five months later, it’s valued at $2B. In between, the company released no new-generation model — the change is entirely on the customer side: CVS Health, Deloitte, and Gallup have all onboarded, using the platform for new-product launch simulations, customer experience optimization, and new-market entry testing. Especially worth noting: CVS Health Ventures went from customer to shareholder — the hardest kind of endorsement to secure in a services business like market research. Reaching $2B just five months after product launch shows this round was chased by investors, not raised because the company needed the money.

WHYThe cost structure of traditional focus groups sets its ceiling: a single study takes weeks and a few dozen people — small sample, long cycle, impossible to repeat. Simile replaces this with simulations that can be run on demand, tuned on the fly, and reproduced at will — essentially turning user research from a one-time purchase into a software call. The fact that Gallup, a company whose core business is polling, is willing to plug in is a very strong signal — even institutions whose stock-in-trade is population samples are handing part of the work to simulation. Its moat is not the model itself, but the real-world cases it has already locked in across healthcare, finance, and consulting — three highly regulated, high-ticket industries. What later entrants have to replicate is this set of reference customers, not the technology.

BUDGETIn this week’s eight funding rounds, Simile is the only high-valuation company with no assets beyond software — its pricing logic is the exact opposite of the energy deals: it doesn’t depend on construction schedules, it depends on replacing an existing line item in corporate budgets. Global annual market-research spending is sitting right there; what investors are buying is the possibility of migrating that budget into software. The next thing to watch isn’t its customer count, but the renewal rate — whether synthetic users are still being treated as a basis for decisions a year from now determines whether that $2B is realized or walked back.

▪ SIGNALWhat’s actually being priced is not simulation accuracy — it’s the migration speed of that annual market-research budget.